Clinical case study.
Turner
M
M
Affonso
A
A
Fudin
J
J
Rivera
W
W
D000085:Acetates / Q000627:therapeutic use*; D000230:Adenocarcinoma / Q000150:complications / Q000556:secondary*; D000588:Amines; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001471:Barrett Esophagus / Q000150:complications*; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary*; D002908:Chronic Disease; D003509:Cyclohexanecarboxylic Acids; D004359:Drug Therapy, Combination; D004938:Esophageal Neoplasms / Q000473:pathology*; D005283:Fentanyl / Q000627:therapeutic use*; D000077206:Gabapentin; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010098:Oxycodone / Q000627:therapeutic use*; D010146:Pain / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control* / Q000523:psychology; D010147:Pain Measurement; D010348:Patient Care Team; D011788:Quality of Life; D013450:Sulfones; D013727:Terminal Care / Q000379:methods*; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003509:Cyclohexanecarboxylic Acids; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D010098:Oxycodone; D005283:Fentanyl